

<b>Name of Sponsor:</b> IRCCS OSPEDALE SAN RAFFAELE - Prof. Fabio Ciceri		<b>Statement on discontinuation of the study</b>	
<b>Investigational Product:</b> Temsirolimus		<b>EudraCT No.:</b> 2008-003870-16	
		<b>Page:</b> 1	
<b>Report Date:</b> 17-SEP-2021	<b>Trial No. / Doc. No.:</b> Allo-Tor		
<b>Title of Trial:</b>	A PILOT STUDY OF SEQUENTIAL, NON-MYELOABLATIVE HLA-IDENTICAL SIBLING DONOR ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWED BY IV TEMSIROLIMUS IN PATIENTS WITH ADVANCED, TKI-REFRACTORY CLEAR-CELL RENA		
<b>Trial Sites:</b>	NA		
<b>Publications:</b>	NA		
<b>Clinical Phase:</b>	II		
<b>Statement on discontinuation of the study:</b>	Only one patient has been enrolled, due to the difficult to find a compatible family donor. Recruitment was also slowed by the introduction of TKIs. Insufficient data for analysis.		